IRA Could Increase Out-of-Pocket Costs for Millions of Part D Seniors, Report Finds

A new analysis by Milliman commissioned by PhRMA indicates that 3.5 million Medicare Part D beneficiaries could face an average 12 percent increase in annual out-of-pocket costs in 2026 due to the Inflation Reduction Act’s (IRA) drug pricing provisions.
Source: Drug Industry Daily